<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>PCOS — DGRefHelp Drafts</title>
  <link rel="stylesheet" href="../assets/site.css" />
</head>
<body>
  <div class="container">
    <div class="header">
      <div class="brand">
        <h1><a href="../index.html">DGRefHelp drafts</a> / PCOS (polycystic ovary syndrome)</h1>
        <div class="sub">Primary care: diagnose (and exclude mimics), manage common symptoms, and know when to refer. Includes triage/referral metrics and safety-net thresholds.</div>
      </div>
      <div class="badges">
        <div class="badge">Mode: quick</div>
        <div class="badge">Last updated: 2026‑02‑09</div>
      </div>
    </div>

    <div class="grid">
      <div class="card">
        <div class="card-hd">
          <div class="tabs" data-tabs>
            <button class="tab" role="tab" data-tab="evidence" aria-selected="true">Evidence</button>
            <button class="tab" role="tab" data-tab="draft" aria-selected="false">DGRefHelp draft</button>
            <button class="tab" role="tab" data-tab="refs" aria-selected="false">References</button>
          </div>
          <div class="copybar">
            <button class="btn" data-copy-target="#draftText">Copy draft</button>
            <button class="btn" data-copy-target="#evidenceText">Copy evidence</button>
          </div>
        </div>

        <div class="card-bd">
          <div class="panel active" role="tabpanel" data-panel="evidence">
            <div id="evidenceText" class="section">
              <h3>Evidence summary (triangulated)</h3>

              <div class="callout ok">
                <strong>Key points for a GP-facing pathway page</strong>
                <ul>
                  <li>Diagnosis in adults is usually based on <strong>Rotterdam criteria (2 of 3)</strong>: oligo/anovulation; clinical/biochemical hyperandrogenism; polycystic ovarian morphology on ultrasound — after excluding other causes.</li>
                  <li>PCOS is often a <strong>metabolic risk state</strong>: screen/monitor for type 2 diabetes risk, cardiovascular risk factors and obesity; address sleep apnoea and mental health where relevant.</li>
                  <li>Symptom-driven management is typical in primary care: <strong>cycle control/endometrial protection</strong>, <strong>hirsutism/acne</strong>, and <strong>fertility goals</strong>.</li>
                  <li><strong>Red flags</strong> for alternative diagnoses: rapid virilisation/rapidly progressive hirsutism, or markedly raised androgens → urgent specialist assessment (often endocrinology).</li>
                </ul>
              </div>

              <h4>Diagnosis (adults) — practical summary</h4>
              <ul>
                <li><strong>Rotterdam criteria (need 2 of 3)</strong>: (1) polycystic ovaries on scan (e.g., ≥12 follicles or ovarian volume &gt;10 cm³ — definitions vary by scan technology), (2) oligo/anovulation, (3) clinical and/or biochemical hyperandrogenism.</li>
                <li><strong>Exclude mimics</strong> (depending on presentation): thyroid disease, hyperprolactinaemia, premature ovarian insufficiency, congenital adrenal hyperplasia, Cushing’s, androgen-secreting tumour.</li>
                <li><strong>Adolescents</strong>: diagnostic criteria differ; avoid over-diagnosis soon after menarche. If needed, a pragmatic rule used in pathways is: wait &gt;2 years after menarche and require BOTH hyperandrogenism and persistent irregular cycles (ultrasound morphology is less helpful).</li>
              </ul>

              <h4>Typical baseline investigations (primary care / community gynae pathways)</h4>
              <ul>
                <li>Androgen profile where indicated: <strong>total testosterone</strong>, <strong>SHBG</strong>, calculate <strong>free androgen index (FAI)</strong>.</li>
                <li>Rule-out tests commonly used: <strong>TSH</strong>, <strong>prolactin</strong>, <strong>FSH</strong> (± LH/oestradiol depending on local pathway/presentation).</li>
                <li>If testosterone markedly high: further adrenal/androgen workup (e.g., DHEA-S, androstenedione, 17‑hydroxyprogesterone) and consider urgent endocrinology.</li>
              </ul>

              <h4>Long-term risk / screening (common themes)</h4>
              <ul>
                <li><strong>Diabetes risk:</strong> consider regular HbA1c screening (some pathways advise annual HbA1c).</li>
                <li><strong>Cardiovascular risk factors:</strong> manage BP, lipids and weight; consider QRISK assessment where appropriate.</li>
                <li><strong>Endometrium:</strong> prolonged oligomenorrhoea/amenorrhoea increases endometrial hyperplasia risk — aim for ≥4 withdrawal bleeds/periods per year using CHC/progestogens/LNG‑IUS as appropriate.</li>
                <li><strong>Pregnancy:</strong> higher gestational diabetes risk; ensure appropriate screening in pregnancy.</li>
                <li><strong>Wellbeing:</strong> consider mood, eating disorder risk, body image and psychosexual impact.</li>
              </ul>

              <div class="callout warn">
                <strong>Local (D&amp;G)</strong>
                <ul>
                  <li>Default routing not yet confirmed for: suspected PCOS diagnosis queries, menstrual symptoms needing specialist input, and ovulation induction/fertility support.</li>
                  <li>If uncertain, refer to <strong>General Gynae clinic</strong>; consider endocrine referral if androgen red flags.</li>
                </ul>
              </div>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="draft">

            <div class="callout" style="margin-bottom:12px">
              <strong>Copy/paste HTML for Right Decisions accordion sections</strong>
              <div class="small">These snippets contain section content only (no internal headings). Paste each into the matching accordion section.</div>
              <div style="height:10px"></div>
              <div class="copybar" style="justify-content:flex-start">
                <button class="btn" data-copy-target="#htmlBackground">Copy Background HTML</button>
                <button class="btn" data-copy-target="#htmlAssessment">Copy Assessment HTML</button>
                <button class="btn" data-copy-target="#htmlPCM">Copy Primary care mgmt HTML</button>
                <button class="btn" data-copy-target="#htmlRefer">Copy Who to refer HTML</button>
                <button class="btn" data-copy-target="#htmlNotRefer">Copy Who not to refer HTML</button>
                <button class="btn" data-copy-target="#htmlRefs">Copy References HTML</button>
              </div>

              <details style="margin-top:10px">
                <summary class="small" style="cursor:pointer">Show HTML snippets</summary>

                <h4 style="margin:12px 0 6px">Background (HTML)</h4>
                <pre id="htmlBackground">&lt;ul&gt;
  &lt;li&gt;PCOS is a common endocrine condition associated with irregular or absent ovulation, hyperandrogenic symptoms (e.g., hirsutism/acne) and metabolic risk.&lt;/li&gt;
  &lt;li&gt;Adult diagnosis is usually based on Rotterdam criteria (need 2 of 3) after excluding other causes: oligo/anovulation; clinical/biochemical hyperandrogenism; polycystic ovarian morphology on ultrasound.&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Assessment (primary care) (HTML)</h4>
                <pre id="htmlAssessment">&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;History:&lt;/strong&gt; cycle pattern (frequency, duration, IMB); acne/hirsutism onset and progression; weight change; fertility goals; symptoms of thyroid disease/hyperprolactinaemia; medication history (androgens/anabolics); sleep apnoea symptoms; mood/eating disorder risk; family history of diabetes/CVD.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Examination:&lt;/strong&gt; BMI, BP; signs of hyperandrogenism; look for virilisation (deep voice, clitoromegaly, rapid muscle gain); consider pelvic exam if abnormal bleeding/pelvic symptoms.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Baseline tests (typical):&lt;/strong&gt; total testosterone; SHBG (calculate free androgen index); TSH; prolactin; FSH (± LH/oestradiol depending on pathway). Consider HbA1c for metabolic risk; pregnancy test if amenorrhoea.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;If androgens markedly raised or rapid virilisation:&lt;/strong&gt; urgent specialist assessment (often endocrinology); consider additional adrenal/androgen tests per local pathway.&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Primary care management (HTML)</h4>
                <pre id="htmlPCM">&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;Lifestyle / metabolic risk:&lt;/strong&gt; support weight management, diet and physical activity; address BP/lipids; consider periodic HbA1c screening (local schedule).&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Endometrial protection (oligo/amenorrhoea):&lt;/strong&gt; aim for ≥4 bleeds/year using combined hormonal contraception (if eligible), cyclical progestogen (e.g., medroxyprogesterone 10 mg OD for 14 days every 2–3 months), or LNG‑IUS.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Hirsutism/acne:&lt;/strong&gt; discuss hair removal; offer combined hormonal contraception (some pathways suggest anti‑androgenic preparations such as co‑cyprindiol or drospirenone-containing CHC if appropriate); consider eflornithine (Vaniqa) for facial hirsutism. Consider specialist advice for anti‑androgen add‑on therapy (e.g., spironolactone) where used locally.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Metformin:&lt;/strong&gt; consider particularly in higher metabolic risk groups (e.g., BMI &gt;30 kg/m² or other diabetes risk factors) if used locally; titrate slowly to tolerance.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Fertility goals:&lt;/strong&gt; optimise weight and comorbidities; early referral if prolonged anovulation or additional infertility risk factors; follow local fertility referral criteria.&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Who to refer (HTML)</h4>
                <pre id="htmlRefer">&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;Endocrinology (consider urgent):&lt;/strong&gt; virilisation or rapidly progressive hirsutism; testosterone &gt;5 nmol/L or &gt;2× upper limit of normal (or per lab/pathway); abnormal adrenal androgen profile suggesting CAH/Cushing’s/adrenal tumour.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Gynaecology:&lt;/strong&gt; persistent abnormal bleeding; prolonged amenorrhoea with abnormal endometrial thickness; suspected endometrial hyperplasia; diagnostic uncertainty; significant symptoms despite primary care management; fertility assessment/ovulation induction as per local pathway.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Dermatology:&lt;/strong&gt; acne not responding to standard acne management and/or requiring isotretinoin consideration.&lt;/li&gt;
&lt;/ul&gt;

&lt;p class=&quot;small&quot;&gt;&lt;strong&gt;Referral letter: suggested information (triage metrics)&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
  &lt;li&gt;Symptoms and duration: cycle pattern; acne/hirsutism; fertility goals; any abnormal bleeding.&lt;/li&gt;
  &lt;li&gt;BMI, BP; relevant comorbidities; smoking; current meds/contraception.&lt;/li&gt;
  &lt;li&gt;Key results (with units and lab ranges): testosterone, SHBG, FAI; TSH; prolactin; FSH (± LH/oestradiol); HbA1c if done.&lt;/li&gt;
  &lt;li&gt;Imaging: ultrasound findings (if performed) and endometrial thickness if abnormal bleeding/prolonged amenorrhoea.&lt;/li&gt;
  &lt;li&gt;Red flags present/absent: virilisation; rapid symptom progression.&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Who not to refer (HTML)</h4>
                <pre id="htmlNotRefer">&lt;ul&gt;
  &lt;li&gt;Typical PCOS symptoms that are responding to lifestyle + primary care treatment, with no red flags and normal/expected androgen levels, can usually be managed in primary care with planned review.&lt;/li&gt;
  &lt;li&gt;Do not refer for “polycystic ovaries on ultrasound” alone without symptoms/biochemical features (confirm local imaging/referral rules).&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">References (HTML)</h4>
                <pre id="htmlRefs">&lt;ol&gt;
  &lt;li&gt;NICE CKS: Polycystic ovary syndrome. https://cks.nice.org.uk/topics/polycystic-ovary-syndrome/ (retrieved 2026‑02‑09)&lt;/li&gt;
  &lt;li&gt;NHS North East London ICB. Pathway: Polycystic Ovary Syndrome (PCOS) (Oct 2024 PDF). https://primarycare.northeastlondon.icb.nhs.uk/wp-content/uploads/2025/01/Pathway-Polycystic-Ovary-Syndrome-10_2024.pdf (retrieved 2026‑02‑09)&lt;/li&gt;
  &lt;li&gt;Whittington Health. Polycystic Ovarian Syndrome Pathway (created Jul 2020; review Jul 2025 PDF). https://www.whittington.nhs.uk/document.ashx?id=14395 (retrieved 2026‑02‑09)&lt;/li&gt;
  &lt;li&gt;RCOG. International Evidence-based Guideline on PCOS (links to Monash 2023 guideline). https://www.rcog.org.uk/guidance/browse-all-guidance/other-guidelines-and-reports/international-evidence-based-guideline-on-polycystic-ovary-syndrome/ (retrieved 2026‑02‑09)&lt;/li&gt;
&lt;/ol&gt;</pre>
              </details>
            </div>

            <div id="draftText" class="section">
              <h3>PCOS (polycystic ovary syndrome)</h3>

              <h4>Background</h4>
              <ul>
                <li>PCOS is associated with irregular or absent ovulation, hyperandrogenic symptoms (e.g., hirsutism/acne) and increased metabolic risk.</li>
                <li>Adult diagnosis is usually based on Rotterdam criteria (need 2 of 3) after excluding other causes: oligo/anovulation; clinical/biochemical hyperandrogenism; polycystic ovarian morphology on ultrasound.</li>
              </ul>

              <h4>Assessment (primary care) — collapsible</h4>
              <ul>
                <li><strong>History:</strong> cycle pattern (frequency/duration; IMB); acne/hirsutism onset and progression; fertility goals; weight change; sleep apnoea symptoms; mood/eating disorder risk; family history of diabetes/CVD; meds (androgens/anabolics).</li>
                <li><strong>Examination:</strong> BMI, BP; hyperandrogenism features; look for virilisation / rapid progression.</li>
                <li><strong>Baseline tests (typical):</strong> total testosterone; SHBG (calculate FAI); TSH; prolactin; FSH (± LH/oestradiol depending on pathway). Consider pregnancy test if amenorrhoea; consider HbA1c for metabolic risk.</li>
                <li><strong>Exclude other causes</strong> depending on presentation: thyroid disease, hyperprolactinaemia, premature ovarian insufficiency, CAH, Cushing’s, androgen-secreting tumour.</li>
              </ul>

              <h4>Primary care management</h4>
              <ul>
                <li><strong>Lifestyle/metabolic:</strong> weight management support; address BP/lipids; consider periodic HbA1c screening (some pathways: annual).</li>
                <li><strong>Endometrial protection (oligo/amenorrhoea):</strong> aim for ≥4 bleeds/year with CHC (if eligible), cyclical progestogen (e.g., medroxyprogesterone 10 mg OD 14 days every 2–3 months), or LNG‑IUS.</li>
                <li><strong>Hirsutism:</strong> discuss hair removal; consider CHC options (some pathways suggest co‑cyprindiol or drospirenone-containing CHC if appropriate); consider eflornithine (Vaniqa) for facial hirsutism (trial ~4 months).</li>
                <li><strong>Acne:</strong> manage per acne guidance; CHC may help; refer dermatology if severe or refractory.</li>
                <li><strong>Metformin:</strong> consider particularly if higher metabolic risk (e.g., BMI &gt;30 kg/m² or diabetes risk factors) if used locally; titrate (GI side effects).</li>
                <li><strong>Fertility goals:</strong> optimise weight/comorbidities; follow local infertility referral criteria; consider early referral if prolonged anovulation or other infertility risks.</li>
              </ul>

              <h4>Who to refer</h4>
              <ul>
                <li><strong>Endocrinology (consider urgent):</strong> virilisation or rapidly progressive hirsutism; testosterone &gt;5 nmol/L or &gt;2× upper limit of normal; abnormal adrenal androgen profile (suspect CAH/Cushing’s/adrenal/ovarian tumour).</li>
                <li><strong>Gynaecology:</strong> persistent abnormal bleeding; prolonged amenorrhoea with abnormal endometrium/endometrial thickness; diagnostic uncertainty; symptoms not controlled with primary care management; fertility/ovulation induction as per local pathway.</li>
                <li><strong>Dermatology:</strong> acne not responding to standard management or requiring specialist therapy.</li>
              </ul>

              <h4>Referral letter: suggested information (triage metrics)</h4>
              <ul>
                <li>Symptoms + duration; cycle pattern; severity of hirsutism/acne; fertility goals; abnormal bleeding.</li>
                <li>BMI, BP; comorbidities; smoking; current contraception/medications; prior treatments tried.</li>
                <li>Key results (with units/ranges): testosterone, SHBG, FAI; TSH; prolactin; FSH (± LH/oestradiol); HbA1c if done.</li>
                <li>Ultrasound results (if done), and endometrial thickness if abnormal bleeding/prolonged amenorrhoea.</li>
                <li>Red flags present/absent: virilisation; rapid progression.</li>
              </ul>

              <h4>Who not to refer</h4>
              <ul>
                <li>Typical symptoms responding to primary care management with no red flags.</li>
                <li>Do not refer for “polycystic ovaries on ultrasound” alone without supportive symptoms/biochemistry (confirm local criteria).</li>
              </ul>

              <h4>Local agreement needed (drafting-site only)</h4>
              <ul>
                <li><label><input type="checkbox" disabled /> Confirm D&amp;G destination for: suspected PCOS diagnosis queries; refractory symptoms; and PCOS-related fertility/ovulation induction.</label></li>
                <li><label><input type="checkbox" disabled /> Confirm local screening cadence (e.g., annual HbA1c vs risk-stratified), and whether lipid profile/BP review is mandated in the pathway.</label></li>
                <li><label><input type="checkbox" disabled /> Confirm local endometrial investigation thresholds in prolonged amenorrhoea/abnormal bleeding (e.g., endometrial thickness cut-offs and whether TVUS is expected prior to referral).</label></li>
                <li><label><input type="checkbox" disabled /> Confirm whether spironolactone is used locally in primary care/community gynae (and required monitoring/contraception advice).</label></li>
              </ul>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="refs">
            <div class="section">
              <h3>References</h3>
              <ol>
                <li>NICE CKS: Polycystic ovary syndrome. <a href="https://cks.nice.org.uk/topics/polycystic-ovary-syndrome/">https://cks.nice.org.uk/topics/polycystic-ovary-syndrome/</a> (retrieved 2026‑02‑09)</li>
                <li>NHS North East London ICB. Pathway: Polycystic Ovary Syndrome (PCOS) (Oct 2024 PDF). <a href="https://primarycare.northeastlondon.icb.nhs.uk/wp-content/uploads/2025/01/Pathway-Polycystic-Ovary-Syndrome-10_2024.pdf">https://primarycare.northeastlondon.icb.nhs.uk/wp-content/uploads/2025/01/Pathway-Polycystic-Ovary-Syndrome-10_2024.pdf</a> (retrieved 2026‑02‑09)</li>
                <li>Whittington Health. Polycystic Ovarian Syndrome Pathway (created Jul 2020; review Jul 2025 PDF). <a href="https://www.whittington.nhs.uk/document.ashx?id=14395">https://www.whittington.nhs.uk/document.ashx?id=14395</a> (retrieved 2026‑02‑09)</li>
                <li>RCOG. International Evidence-based Guideline on PCOS (links to Monash 2023 guideline). <a href="https://www.rcog.org.uk/guidance/browse-all-guidance/other-guidelines-and-reports/international-evidence-based-guideline-on-polycystic-ovary-syndrome/">https://www.rcog.org.uk/guidance/browse-all-guidance/other-guidelines-and-reports/international-evidence-based-guideline-on-polycystic-ovary-syndrome/</a> (retrieved 2026‑02‑09)</li>
              </ol>
            </div>
          </div>

        </div>
      </div>
    </div>
  </div>

  <script src="../assets/site.js"></script>
</body>
</html>
